Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.71 |
| ▸ | CDK2 | P24941 | 11/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27370878 | 0.90 | GSK3B (0.72) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12953359 | 0.88 | GSK3B (0.69) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12953189 | 0.87 | GSK3B (0.71) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL27369472 | 0.87 | GSK3B (0.76) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12954111 | 0.85 | CDK2 (0.74) | GSK3BCDK2CCNE1 | |
| SCHEMBL27370456 | 0.84 | GSK3B (0.69) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12953029 | 0.83 | GSK3B (1.00) | GSK3BCDK2CCNE1 | |
| SCHEMBL30356813 | 0.82 | GSK3B (0.70) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12953181 | 0.80 | GSK3B (0.64) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12954514 | 0.78 | GSK3B (0.61) | GSK3BCDK2CCNE1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885CDK2 1/4885CCNE1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.